Core Insights - Stonegate Capital Partners has initiated coverage on AB Science S.A., focusing on its late-stage biotech asset, masitinib, which is an oral, selective tyrosine kinase inhibitor aimed at modulating maladaptive neuroinflammation [1] Company Overview - AB Science is advancing masitinib as an add-on therapy for conditions such as ALS (Amyotrophic Lateral Sclerosis), progressive MS (Multiple Sclerosis), and Alzheimer's Disease (AD) [1] - The company is also developing AB8939 for Acute Myeloid Leukemia (AML), indicating a diverse pipeline [1] Clinical Development - The ALS program is supported by prior Phase 2b/3 data, enhancing confidence in its efficacy [6] - For progressive MS, a Phase 3 trial has been authorized in the US and 12 EU countries, with approximately 94 sites initiating the study [6] - Financing for these trials is supported by grants, indicating a solid financial backing for ongoing research [6]

Core Points - The web conference organized by AB Science aims to provide an update on the clinical development of their lead drug, AB8939 [1][3] - The presentation will be technical in nature, focusing on the progress of AB8939, which is currently in Phase I of clinical trials [3] Group 1 - Alain Moussy serves as the Co-Founder, Chairman, President, CEO, MD, and Scientific Director of AB Science [1] - The conference features notable experts including Nicholas Short, Olivier Hermine, and Christian Auclair, who contribute to the scientific and clinical aspects of the drug development [2] - Laurent Guy, the Chief Financial Officer, will address questions from participants at the end of the presentation [2]